

# EMERGING MARKETS HEMATOLOGY SUMMIT 3<sup>RD</sup> WAVE

**11-12  
OCTOBER  
2024**


**CROWNE PLAZA FLORYA, ISTANBUL**

[CLICK HERE TO REGISTER NOW](#)

## DAY ONE (MM) SPEAKERS




**DR. ABDELLAH MADANI**  
Head of the Hematology Department  
University Hospital 20 Août,  
Casablanca, Morocco




**DR. AHMAD ALHURAJI**  
Consultant Hematologist,  
Kuwait Cancer Control  
Center, Kuwait City, Kuwait



**DR. AHMED MAGDY**  
Assistant Professor of Medical  
Oncology and Hematology  
National cancer institute  
(NCI) Head of Medical  
Oncology Department  
Shifa Hospital Cairo, Egypt



**DR. ALI BAZARBACHI**  
Professor of Medicine,  
Hematology and Oncology  
Professor of Anatomy, Cell  
Biology and Physiological  
Sciences Director, Bone  
Marrow Transplantation  
Program, American University  
of Beirut, Medical Center,  
Lebanon




**DR. AYMAN ALHEJAZI**  
Assistant Professor at King  
Saud bin Abdulaziz University  
for Health Sciences,  
Riyadh, KSA




**DR. DAVID BRITTAIN**  
Clinical Hematologist  
Alberts Cellular Therapy  
Haematology Services  
Pretoria, South Africa



**DR. DEENA MUDAWI**  
Hematology consultant –  
National Center for Cancer  
Care and Research, Hamad  
Medical Center, Doha, Qatar




**DR. INASEL-NAJJAR**  
Consultant, Adult Hematology &  
Bone Marrow Transplant /  
Director Undergraduate &  
Advance Program at Abu  
Dhabi stem cell center , UAE




**DR. MAHMOUD MARASHI**  
Consultant Hematologist  
Mediclinic City Hospital,  
Dubai, UAE




**DR. MAJED AL AHMADI**  
Consultant, Adult Hematology /  
BMT King Abdulaziz Medical  
City, National Guard Health  
Affairs – Jeddah, KSA




**DR. MARIA-VICTORIA  
MATEOS**  
Consultant Physician in the  
Hematology Department  
and Associate Professor of  
Medicine at the University  
of Salamanca, Spain.




**DR. MERVAT MATTAR**  
Head and founder  
Hematology department  
Cairo University Cairo, Egypt




**DR. MOHAMED ABD EL  
MOITY**  
Professor of Hematology  
And Dean of National  
Cancer Institute Egypt  
Cairo, Egypt




**DR. MOHAMAD HAIDAR**  
Consultant Hematologist  
Zahraa University Hospital  
Beirut, Lebanon



**DR. MOHAMMED KAMIL**  
Consultant Haematologist  
Baghdad Medical City  
Hematology Center  
Baghdad, Iraq




**DR. MOHAMAD MOHTY**  
Professor of Hematology,  
Head of the Hematology and  
Cellular Therapy Department,  
Sorbonne University, Paris,  
France




**DR. OMAR ABDULJALIL**  
Consultant of Adult  
Hematology and Stem cell  
transplant at King Fahad  
Specialist Hospital Dammam,  
KSA




**DR. ÖMÜR GÖKMEN  
SEVINDIK**  
Professor at  
Istanbul Florence Nightingale  
Hastanesi, Türkiye



**DR. RAAFAT ABD ELFATTAH**  
Professor of Hematology  
Head of Hematology  
Department  
King Hussein Cancer Institute  
Cairo, Egypt



**DR. RUBA TAHA**  
Senior consultant  
Hematology – BMT  
Department  
National Center for Cancer  
Care and Research  
Hamad Medical Corporation  
HMC , Qatar



**DR. SAMEER YASER**  
Consultant Medical Oncology.  
Head of myeloma service  
King Hussein Cancer Center.  
Amman , Jordan



**DR. SAUD ALHAYLI**  
Consultant Hematologist and  
BMT at King Faisal Specialized  
Hospital and Research  
Center, Riyadh, KSA



**DR. SHABEEHA RANA**  
Consultant Hematologist,  
Genesis Healthcare Center,  
Dubai, UAE



**DR. VADIM PTUSHKIN**  
Head of Hematology  
Department Moscow Botkin  
Hospital, Russia

**DAY 1**

**FRIDAY  
11 OCTOBER**

TIME	TOPIC	SPEAKER
9:00 9:15	Welcome & Scientific Day Opening	
<b>Session 1: Multiple Myeloma Fundamentals</b>		
Chairman: Dr. Maria-Victoria Mateos Dr. Omür Gökmen Sevinik		
9:15 9:40	Navigating towards cure in TEM: Impact of quadruplet therapy	Dr. Mervat Mattar
9:40 10:05	Pioneering the path to cure in TEM: Redefining the standard of care	Dr. Mohamad Mohty
10:05 10:30	Optimal treatment approaches for high-risk MM pts	Dr. Ahmad Alhuraiji
10:30 10:45	Panel Discussion	Panelist
<b>Session 2: Refining MM treatment strategies following first relapse</b>		
Chairman: Dr. Mohamad Haidar		
10:45 10:55	Effective treatment approaches for first relapse in Lenalidomide refractory patients	Dr. David Brittain
10:55 11:05	Effective treatment approach for first relapse in Lenalidomide sensitive patients	Dr. Majed Al Ahmadi
11:05 11:15	Role of anti-CD38 retreatment in RRMM	Dr. Vadim Ptushkin
11:15 11:25	Panel Discussion	All
11:25 11:45	Coffee Break	
11:45 11:50	Mid-day opening	
<b>Session 3a: Evolving MM treatment paradigm</b>		
Chairman: Dr. Shabeeha Rana		
11:50 12:10	Emerging treatment algorithms with chimeric antigen receptor T cell therapy	Dr. Saud Alhaili
12:10 12:30	Bispecifics in MM: Bridging gaps with innovative treatments	Dr. Ali Bazarbachi
12:30 12:50	BCMA Bispecifics in MM: Prevention and management of adverse events	Dr. Maria-Victoria Mateos
12:50 13:10	Panel Discussion	All
<b>Session 3b: Evolving MM treatment paradigm</b>		
Chairman: Dr. Raafat Abd Elfattah		
13:10 13:30	Non-Bispecifics in MM: Prevention and management of adverse events	Dr. Maria-Victoria Mateos
13:30 13:50	Supportive care in multiple myeloma: current practice	Dr. Inas El-Najjar
13:50 14:05	Panel Discussion	All
14:05 14:10	Workshop guidance	
14:10 15:10	Lunch break	

## FRIDAY WORKSHOPS

Each HCP will choose two workshops

[CLICK HERE TO REGISTER NOW](#)

### Session 4: Therapeutic Showdown: The Great Debate

**Workshop 1:**  
Beyond the  
guidelines in newly  
diagnosed multiple  
myeloma

**Workshop 2:**  
Relapsed/Refractory  
MM patients

**Workshop 3:**  
High risk MM  
patients

**Moderator:**  
Dr. Mohamad Mohty

**Moderator:**  
Dr. Sameer Yaser

**Moderator:**  
Dr. Mohamed Abd el Moaty

**Case Debate 1:**  
Implication of MRD  
negativity and treatment  
duration in transplant  
eligible MM

**Case Debate 1:**  
Indication of BCMA  
bispecific treatment  
in RRMM patients

**Case Debate 1:**  
Treatment  
approach in  
extramedullary MM

Dr. Ali Bazarbachi

Dr. Ayman Alhejazi

Dr. Ahmed Magdy

**Case Debate 2:**  
Treatment selection and  
duration for transplant  
ineligible MM

**Case Debate 2:**  
Indication of  
non-BCMA  
bispecific in RRMM  
patients

**Case Debate 2:**  
Treatment approach in  
high cytogenetic risk  
patient

Dr. Abdellah Madani

Dr. Maria-Victoria  
Mateos

Dr. Mohammed Kamil

**Case Debate 3:**  
Treatment approach  
of frail TIEMM patients

**Case Debate 3:**  
Use of bispecific  
treatments in triple  
class refractory  
multiple myeloma

**Case Debate 3:**  
Treatment  
approach in MM  
patients with renal  
failure

Dr. Omar Abduljalil

Dr. Deena Mudawi

Dr. Ruba Taha

Panel Discussion

Panel Discussion

Panel Discussion

Coffee break & Breakout session shift

## ROUND TWO

**Case Debate 1:**  
Implication of MRD  
negativity and treatment  
duration in transplant  
eligible MM

**Case Debate 1:**  
Indication of BCMA  
bispecific treatment  
in RRMM patients

**Case Debate 1:**  
Treatment  
approach in  
extramedullary MM

Dr. Ali Bazarbachi

Dr. Ayman Alhejazi

Dr. Ahmed Magdy

**Case Debate 2:**  
Treatment selection and  
duration for transplant  
ineligible MM

**Case Debate 2:**  
Indication of  
non-BCMA  
bispecific in RRMM  
patients

**Case Debate 2:**  
Treatment approach in  
high cytogenetic risk  
patient

Dr. Abdellah Madani

Dr. Maria-Victoria  
Mateos

Dr. Mohammed Kamil

**Case Debate 3:**  
Treatment approach  
of frail TIEMM patients

**Case Debate 3:**  
Use of bispecific  
treatments in triple  
class refractory  
multiple myeloma

**Case Debate 3:**  
Treatment  
approach in MM  
patients with renal  
failure

Dr. Omar Abduljalil

Dr. Deena Mudawi

Dr. Ruba Taha

Panel Discussion

Panel Discussion

Panel Discussion

End of Day One

## DAY TWO (CLL) SPEAKERS



**DR. ABDULNASER NOURALLAH**  
Hematology/Oncology  
Consultant  
Mansoura General Hospital  
Khabar, KSA



**DR. AHMAD ALHURAJI**  
Consultant Hematologist,  
Kuwait Cancer Control  
Center, Kuwait City, Kuwait



**DR. ANAS HAMAD**  
Director of Pharmacy  
Department at Qatar's  
National Center for Cancer  
Care & Research and Head of  
Medication Safety & Quality  
Center, Qatar



**DR. EUGENE NIKITIN**  
Head of the Day Hospital of  
Hematology, Oncology and  
Immunology, Moscow  
Federation, Moscow



**DR. GAMAL ELDIN FATHY**  
Professor of Hematology  
Nasser Institute Egypt




**DR. GÜLDANE CENGİZ SEVAL**  
Associate Professor  
Ankara University  
Faculty of Medicine Turkey




**DR. HANI SABBOUR**  
Staff Physician,  
Cardiovascular Medicine,  
Heart, Vascular & Thoracic  
Institute Mediclinic, Abu  
Dhabi, UAE




**DR. HASAN AL-YASEEN**  
Consultant Hematologist  
Dubai Hospital, Dubai, UAE




**DR. MAHMOUD SALAH**  
Professor Of Hematology  
and head of oncology  
hematology department  
International Medical Center  
Cairo, Egypt




**DR. MANSOUR ALFAYEZ**  
Consultant Hematologist  
King Faisal Specialist Hospital  
and Research Center  
Riyadh, KSA




**DR. MARTIN TREPEL**  
Direktor der II. Med. Klinik  
Direktor des Comprehensive  
Cancer Centers Augsburg  
Facharzt für Innere Medizin,  
Hämatoologie, Onkologie  
University of Augsburg,  
Germany




**DR. MICHAEL CASS**  
Clinical Haematologist  
Haemodialysis – Netcare  
Kullisriver, Cape Town, South  
Africa




**DR. MOHAMED MOUSA**  
Professor of Hematology  
Ain Shams University Egypt



**DR. NAEEM ARSHAD  
CHAUDHRI**  
Hematology consultant  
King Faisal Specialized  
Hospital and research Center  
Riyadh, KSA




**DR. RACHEL EL FERKH,**  
Associate Professor or  
Hemato-Oncology at Geitaoui  
Hospital, Beirut, Lebanon



**DR. SALEM AL SHEMMARI**  
Consultant, Department of  
Hemato-Oncology  
Kuwait Cancer Control Center  
Associate Professor  
Department of Medicine  
Kuwait University



**DR. TISSIR RAJAA**  
Professor Hematology  
Head of Hematology unit at  
Mohammed VI International  
University Hospital,  
Casablanca, Morocco



**DR. ZOUBIDA TAZI MEZALEK**  
Head of the Hematology Unit,  
University Hospital Ibn Sina,  
Rabat, Morocco

**DAY 2**

**SATURDAY  
12 OCTOBER**

TIME	TOPIC	SPEAKER
<b>Session 1: The practical management of AL Amyloidosis</b>		
Chairman: Dr. Michael Cass Dr. Güldane Cengiz Seval		
09:00 09:15	Understanding the fundamentals of AL Amyloidosis	Dr. Hani Sabbour
09:15 09:30	Practical management and treatment of AL Amyloidosis	Dr. Zoubida Tazi Mezalek
09:30 09:35	Panel Discussion	All
<b>Session 2: The ABC's of CLL: A regional perspective</b>		
Chairman: Dr. Martin Trepel		
09:35 10:05	Round Table Discussion • Pre-Screening (suitable patients) • CIT vs novel therapies • IV treatment in NDCLL	Dr. Michael Cass Dr. Tissir Rajaa Dr. Mansour Alfayez
<b>Session 3a: The evolution of treatment &amp; management in CLL</b>		
Chairman: Dr. Mahmoud Salah		
10:05 10:20	Definition of fitness in CLL	Dr. Martin Trepel
10:20 10:30	Advances in treatment management in ND mutated IGHV with and without 17p del	Dr. Martin Trepel
10:30 10:45	Advances in treatment management of ND unmutated IGHV patients	Dr. Mansour Alfayez
<b>Session 3b: The evolution of treatment &amp; management in CLL</b>		
Chairman: Dr. Mahmoud Salah		
10:45 10:55	Russian RWE	Dr. Eugene Nikitin
10:55 11:05	Upfront Fixed Duration Treatment in CLL: A position statement from Gulf region.	Dr. Anas Hamad
11:05 11:20	Sequencing of CLL treatment management.	Dr. Martin Trepel
11:20 11:30	Panel Discussion	All
11:30 11:45	Coffee Break	
<b>Session 4: Cardio-Hematology: Practical management of BTKis</b>		
Chairman: Dr. Abdulnaser Nourallah		
11:45 11:55	Understanding Cardiovascular Management of BTK Inhibitors : Cardiology Perspective	Dr. Hani Sabbour
11:55 12:05	Lessons from the region (GCC consensus on managing cardiovascular toxicities in hematological malignancies).	Dr. Ahmad Alhuraiji
12:05 12:15	Panel Discussion	All
12:15 12:20	Workshop opening	
<b>Session 5a: Case Study Presentations</b>		
Chairman: Dr. Naeem Arshad Chaudhri		
12:20 12:35	IGHV mutated patients – the optimal therapy and management plan	Dr. Martin Trepel
12:35 12:50	IGHV unmutated patients – where to from here?	Dr. Gamal Eldin Fathy
12:50 13:00	Panel Discussion	All
<b>Session 5b: Case Study Presentations</b>		
Chairman: Dr. Hasan Al-Yaseen		
13:00 13:15	The evolution of managing a patient with BTKi in unfit patients	Dr. Mohamed Mousa
13:15 13:30	Optimizing BTKi therapy in patients with a del17p mutation	Dr. Rachel El Ferkh
13:30 13:40	Panel Discussion	All
13:40	Symposium closing & Lunch	

